IO Summit: RenMab Mouse – A Leading Platform for Fully Human Antibody Generation
With the development of immuno-oncology, therapeutic antibodies have been proven to be extraordinarily effective for cancer treatment. Conventional human antibody discovery process can be divided into stages including target selection and validation, screening preparation, hits generation, leads selection and optimization, and clinical candidate selection. To accelerate antibody development process, Biocytogen has developed RenMab™ Mouse, a fully human antibody mouse whose entire mouse variable regions were replaced by human Immunoglobulin heavy chain and κ light chain through Biocytogen’s unique Mb-scale chromosome engineering technology. RenMab™ Mouse provides an efficient therapeutic antibody discovery platform for fully human antibody hit generation and characterization. We have characterized RenMab™ Mouse with the following features.
- The entire mouse variable regions were replaced with complete human genome DNA in situ for complete human & mouse regulatory elements. The gene regulation of RenMab™ mouse is highly consistent with that of human.
- Mouse constant region remains to ensure proper B cell development and maturation. Immune system of RenMab™ Mouse has been proven to be almost identical to that of wild type mouse. RenMab™ Mouse showed normal antibody immune responses to antigens.
- RenMab™ Mouse generates a highly diverse repertoire of fully human antibody variable regions through V(D)J recombination. This capability can lead to promising hits for downstream leads and candidate selection in human therapeutic antibody discovery programs.